Regional Analysis
Global Calcineurin Inhibitor Market- Regional Insights
- North America: North America is expected to dominate the calcineurin inhibitor market during the forecast period. The high prevalence of autoimmune diseases, such as psoriasis, atopic dermatitis, and ulcerative colitis, in the region is driving growth of the market. Rising number of organ transplants in the region is also contributing to the growth of the market. It holds 36.2 % market share.
- Europe: Europe is expected to be the second-largest market for calcineurin inhibitor during the forecast period. The high prevalence of autoimmune diseases and organ transplants in the region is driving the growth of the market. Increasing focus on research and development in the region is also contributing to the growth of the market. It holds 18% market share.
- Asia Pacific: Asia Pacific is expected to be the fastest-growing market for calcineurin inhibitor during the forecast period. Rising awareness about autoimmune diseases and organ transplants in the region is driving the growth of the market. Growing geriatric population in the region is also contributing to the growth of the market. It holds 27.2% market share.
Geographies covered:
- North America: U.S. and Canada
- Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
- Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
- Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
- Middle East & Africa: GCC Countries, Israel, South Africa, North Africa, and Central Africa and Rest of Middle East
U.S.: 
U.K. : 
India : 
